Michelle Lally serves as the Director of the HIV Vaccine Clinical Trials Unit for Brown University/The Miriam Hospital; her primary research interests include HIV prevention, testing, and vaccine development. Her attention also focuses on health care disparity, access to HIV and other STD education, testing, and treatment, and the representation of women and minorities in clinical trials. She has also worked extensively in the area of rapid HIV testing and its potential community applications.

Biography

Following her graduation from Boston College magna cum laude with a degree in Biochemistry and Philosophy in 1989, Dr. Michelle Lally pursued her education in medicine at the University of Virginia School of Medicine. She graduated in 1993, and continued her post-graduate training with an Internship in Internal Medicine and Residency in Internal Medicine at the New England Deaconess Hospital, affiliated with Harvard Medical School, where from 1996-1997 she served as a clinical fellow in Infectious Diseases. She then completed her Research Fellowship in Infectious Diseases at Beth Israel Deaconess Medical Center and remained at the Harvard School of Public Health to earn her M.Sc. in Epidemiology in 1999. She accepted an Assistant Professorship at Brown University Medical School that same year.

Institutions

Mh

Awards

Appointments

1996-1998: Clinical Trials Physician, Adult Clinical Trials Group, Beth Israel Deaconess Medical Center

1999-2001: Clinical Trials Physician, HIV Vaccine Clinical Trials Unit, The Miriam Hospital/Brown University

2001 to present: Director, HIV Vaccine Clinical Trials Unit. The Miriam Hospital/Brown University

2002: Protocol Co-Chair, HVTN 049

2002 to present: Member, HIV Vaccine Trials Network Adolescent Working Group

2006-2007: Invited Co-Chair, NIH Working Group on HIV Viral Load Detection: Rapid Assays and the use of Dried Blood Spots

2006 to present: Member, HVTN Adolescent Trials Coordinating Group

2006 to present: HIV Vaccine Trials Network (HVTN) Adolescent Representative and Liaison

2006 to present: Invited Member, HVTN Representative, The Vaccine/Immuno-based Therapy Scientific Committee (Vaccine SC) of the International, Maternal Pediatric Adolescent AIDs Clinical Trials (IMPAACT) Group


2008 to present: Member, Adolescent Medicine Leadership Group of the Adolescent Trials Network (ATN)

2008-2010: Director, University Medicine Foundation, Travel and Vaccination Clinic


Honors and Awards

2000-2002: Preceptorship Award: "an outstanding teacher in medicine." Rhode Island Hospital, The Miriam Hospital, and Brown University

2002: Dean's Teaching Excellence Award: "In regognition of exemplary teaching in BIO 282 Infectious Disease Pathophysiology", Brown Medical School

2007: Dean's Teaching Excellence Award: "In recognition of exemplary teaching in 351 Infectious Disease Pathophysiology", Brown Medical School

2011-Present: Director, Brown University AIDS Program (BRUNAP)

2011-Present: Elected Chair, Community Prevention Leadership Group (CPLG) of the Adolescent Medicine Trials Network (ATN)

Affiliations

Brown University
The Miriam Hospital (A Lifespan Partner)

Funded Research

CURRENT GRANTS
1. HIV Vaccine Trials Network Liaison for Adolescent Trials
HIV Vaccine Trials Network at Fred Hutchinson Cancer Research Center/ NIH -
5U01AI068614

6/1/06-5/31/13: $10,500/year: $365,363/ anticipated total award (year by year subcontract)
Principal Investigator: Michelle A. Lally, MD, MSc

HVTN leadership position to serve as lead HVTN investigator for adolescent issues, and as liaison to other NIH-sponsored networks, the Adolescent Medicine Trials Network (ATN) the International Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT), in an effort to facilitate the development of adolescent HIV vaccine trials.

2. Adolescent Trials Network: Adolescent Medicine Leadership Group/ NIH-1U01HD040533

03/01/08-02/28/13: $70,000/year: $93,342/ anticipated total award (year by year subcontract)
Principal Investigator: Michelle Lally, MD, MSc

Asked to support the Adolescent Medicine Leadership Group and to serve as the Chair of the Community Prevention Leadership Group of the NIH-funded ATN in the formulation of hypotheses and review of proposals submitted to the Network for scientific merit and feasibility. The primary mission of the ATN is to explore promising behavioral, microbicidal, prophylactic, therapeutic, and vaccine modalities in HIV-infected and HIV at-risk adolescents, age 12 through 24.

3. RV284: Cohort Development to Determine Genetic Mechanisms of Protection from HIV-1 Acquisition Among Persons at Risk for HIV infection/ Henry Jackson Foundation- W8IXWH-07-2-0067
8/1/09-9/30/14: $1,666,778/total award
Principal Investigator: Michelle Lally, MD, MSc

This project aims to develop a cohort of persons at risk for HIV infection through HIV exposure in order to determine genetic markers of protection from HIV infection.

4. Project to Explore the Proteomics of HIV/ NIH (ARRA)
3P30AI042853-13S1 (CFAR Supplement)
8/30/10-7/31/12: $114,348/ total award (directs)
Principal Investigator: Michelle Lally, MD, MSc

This project aims to explore the proteomic variability among persons with HIV who control their disease as compared to non controllers, and also among persons with HIV exposure.

5. A Phase III Randomized, International, Placebo-Controlled, Double-Blind Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine: Merck 503-006

2/02/10-Indefinite: 49,500/ total award (directs)
Principal Investigator: Michelle Lally, MD, MSc

This Phase III study is evaluating the efficacy of a Multivalent PHV vaccine.

6. New England AIDS Education and Training Center
7/01/11-6/30/12: $27,500/year
Principal Investigator: Michelle Lally, MD, MSc

This project supports the training and education of HIV care providers throughout New England. Dr. Lally is the PI of the Rhode Island local performance site for this project and oversees Rhode Island based trainees as well as Rhode Island LED trainings throughout New England.

Teaching Experience

1998 to present: Infectious Disease Attending, The Miriam Hospital, Providence, RI

2000-2003: BI0282 Pathophysiology, Infectious Diseases, Brown University, Providence, RI (Small Group Sessions Facilitator)

2005 to present: Fellows Lecture Series, Rhode Island Hospital, Providence, RI

2005 to present: Resident Lecture Series, The Miriam Hospital, Providence, RI

2007-present: BIO365 Pathophysiology, Infectious Diseases, Brown University, Providence, RI (Small Group Sessions Facilitator)

View My Full Publication List in pdf format

Selected Publications

• Ma M, Kibler JL, Vigil-Otero A, Sarpong D, Lally M, Mayer KH. Correlates of Willingness to Participate in Microbicide Research among African Americans. J Health Psychology [epub 2/24/12](2012)
• Spearman P, Lally MA, Elizaga M, Ontefiori D, Tomaras GD, McElrath MJ, Hural J, DeRosa SC, Sata A, Huang Y, Frey SE, Sato P, Donnelly J, Barnett S, Corey LJ, and the HIV Vaccine Trials Network of NIAID. A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers. J Infect Dis 203(8):1165-73, 2011. PMC3068023(2011)
• Churchyard GJ, Morgan C, Adams E, Hural J, Graham BS, Moodie Z, Grove D, ray G, Bekker LG, McElrath MJ, Tomaras GD, Goepfert P, Kalams S, Baden LR, Lally MA, Dolin R, Blattner W, Kalichman A, Figueroa JP, Paper J, Schechter M, Defawe O, DeRosa SC, Montefiori DC, Nabel GJ, Corey L, Keefer MC. A phase IIA study of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 boost in healthy adults: a randomized clinical trial (HVTN204). PloS ONE 03 Aug 2011. PMC3152265(2011)
• Nugent NR, Lally M, Brown L, Knopik V, McGeary J. OPRMI and diagnosis related posttraumatic stress disorder in binge-drinking patients living with HIV. AIDS and Behavior [Epub 12/6/11].(2011)
• Rudy BJ, Kapogiannis BG, Lally MA, Gray GE, Bekker LG, Krogstad P, McGowan I. Youth-specific considerations in the development of preexposure prophylaxis, microbicide, and vaccine research trials. J Acquir Immune Defic Syndr 54 Suppl 1:S31-42, 2010. PMC2912697(2010)
• Henderson CE, Rich JD, Lally MA. HPV vaccination practices among juvenile justice facilities in the United States J Adolesc Health 46(5):495-8, 2010. PMC2927822(2010)
• Harro CD, Robertson MN, Lally MA, O'Neill LD, Edupuganti S, Goepfert PA, Mulligan MJ, Pridd FH, Dubey SA, Kierstead LS, Sun X, Casimiro DR, DiNubile MJ, Shiver JW, Leavitt RY, Mehrotra DV, for the Merck V520-007/012 Study Groups. Safety and immunogenicity of adenovirus-vectored near-consensus HIV type 1 Clade B gag vaccines in healthy adults. AIDS Res Hum Retroviruses 25(1):103-14, 2009. PMC3256563(2009)
• Priddy FH, Brown D, Kublin J, Monahan K, Wright DP, Lalezari J, Santiago S, Marmor M, Lally MA, Novak RM, Brown SJ, Kulkarni P, Dubey SA, Kierstead LS, Casimiro DR, Mogg R, DiNubile MJ, Shiver JW, Leavitt RY, Robertson MN, Mehrotra DV, Quirk E, for the Merck V520-016 Study Group. Safety and immunogenicity of a replication-incompetent adenovirus type-5 HIV-1 Clade B gag/pol/nef vaccine in healthy adults. Clin Infect Dis 46(11):1769-81, 2008. (Free full text)(2008)
• Lally MA, Montstream-Quas S, Tanaka S, Tedeschi S, Morrow K. A qualitative study among injection drug using women in Rhode Island: attitudes toward testing, treatment, and vaccination for hepatitis and HIV. AIDS Pt Care STDs 22(1):53-64, 2008. NIHMSID 345198 PMC3291495(2008)
• Quirk EK, Mogg R, Brown DD, Lally MA, Mehrotra DV, DiNubile MJ, Robertson MN. HIV seroconversion without infection after receipt of adenovirus-vectored HIV-1 vaccines. Clin Infect Dis 47(12):1593-9, 2008. (Free full text)(2008)
• Beckwith CG, Cohen J, Shannon C, Raz L, Rich JD, Lally MA. HIV testing experiences among male and female inmates in Rhode Island. AIDS Reader 17(9):459-64, 2007.(2007)
• Beckwith CG, Atunah-Jay S, Cohen J, Macalino G, Poshkus M, Rich JD, Flanigan TP, Lally MA. Feasibility and acceptability of rapid HIV testing in jail. AIDS Pt Care STDs 21(1):41-7, 2007.(2007)
• Tedeschi SK, Bonney LE, Manalo R, Mayer KH, Shepardson S, Rich JD, Lally MA. Vaccination in juvenile correctional facilities: state practices, hepatitis B, and the impact on anticipated sexually transmitted infection vaccines. Pub Health Rep 122(1):44-8, 2007. PMC1802118(2007)
• Lally MA, Gaitanis MD, Vallabhaneni S, Reinert S, Mayer K, Zimet G, Rich JD. Willingness to receive an HIV vaccine among incarcerated persons. Prev Med 43(5):402-405, 2006. PMC3249390(2006)
• Lally MA, MacNevin R, Sergie Z, Hitt R, DiSpigno M, Cenedella C. Stein MD. A model to provide comprehensive testing for HIV, viral hepatitis, and sexually transmitted infections at a short-term drug treatment center. AIDS Pt Care STDs 19(5):298-306, 2005. PMC1852463(2005)